Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification
Christella E. Widjaja, … , Huib Ovaa, John T. Chang
Christella E. Widjaja, … , Huib Ovaa, John T. Chang
Published August 28, 2017
Citation Information: J Clin Invest. 2017;127(10):3609-3623. https://doi.org/10.1172/JCI90895.
View: Text | PDF
Research Article Immunology

Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification

  • Text
  • PDF
Abstract

During an immune response, CD8+ T lymphocytes can undergo asymmetric division, giving rise to daughter cells that exhibit distinct tendencies to adopt terminal effector and memory cell fates. Here we show that “pre-effector” and “pre-memory” cells resulting from the first CD8+ T cell division in vivo exhibited low and high rates of endogenous proteasome activity, respectively. Pharmacologic reduction of proteasome activity in CD8+ T cells early during differentiation resulted in acquisition of terminal effector cell characteristics, whereas enhancement of proteasome activity conferred attributes of memory lymphocytes. Transcriptomic and proteomic analyses revealed that modulating proteasome activity in CD8+ T cells affected cellular metabolism. These metabolic changes were mediated, in part, through differential expression of Myc, a transcription factor that controls glycolysis and metabolic reprogramming. Taken together, these results demonstrate that proteasome activity is an important regulator of CD8+ T cell fate and raise the possibility that increasing proteasome activity may be a useful therapeutic strategy to enhance the generation of memory lymphocytes.

Authors

Christella E. Widjaja, Jocelyn G. Olvera, Patrick J. Metz, Anthony T. Phan, Jeffrey N. Savas, Gerjan de Bruin, Yves Leestemaker, Celia R. Berkers, Annemieke de Jong, Bogdan I. Florea, Kathleen Fisch, Justine Lopez, Stephanie H. Kim, Daniel A. Garcia, Stephen Searles, Jack D. Bui, Aaron N. Chang, John R. Yates III, Ananda W. Goldrath, Hermen S. Overkleeft, Huib Ovaa, John T. Chang

×

Figure 5

Proteasome activation enhances generation of central memory CD8+ T cells in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Proteasome activation enhances generation of central memory CD8+ T cells...
(A) Percentages of CD45.1+ vehicle- and proteasome activator–treated CD8+ T cells, analyzed by flow cytometry on day 7 after infection. (B) Percentage of KLRG1hiIL-7Rlo and KLRG1loIL-7Rhi cells, gated on CD45.1+ CD8+ cells. (C) T-bet and Eomes expression within gated CD45.1+CD8+ cells, as in I. (D) Percentages of CD45.1+ vehicle- and proteasome activator–treated CD8+ T cells, analyzed by flow cytometry on day 50 after infection. (E) Percentage of KLRG1hiIL-7Rlo and KLRG1loIL-7Rhi cells, gated on CD45.1+ CD8+ cells. (F) T-bet, Eomes, or Bcl-2 expression (MFI) and percentages of cells expressing CD122, CD27, or CD62L; cells were gated on CD45.1+CD8+ T cells as in L. (G) Proliferative response of CD45.1+ CD8+ T cells in response to re-infection with 105 CFU Lm-OVA in immune mice that had received cells treated with vehicle or proteasome activator 50 days prior. (A–G) Data are representative of at least 2 independent experiments with n ≥ 4 mice per group; error bars represent SEM of 3 replicates. N.S., P > 0.05; *P < 0.05, **P < 0.01 (Student’s t test).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts